Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 250 Carcinoma, Non-Small-Cell Lung 86 Carcinoma, Renal Cell 62 Neoplasm Metastasis 53 Neoplasms 51 Prostatic Neoplasms 35 Lung Neoplasms 32 Uveal Melanoma 29 Pancreatic Neoplasms 28 Carcinoma, Hepatocellular 25 Brain Neoplasms 24 Colorectal Neoplasms 23 Sarcoma 22 Breast Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 18 Small Cell Lung Carcinoma 18 Kidney Neoplasms 18 Skin Neoplasms 17 Diabetes Mellitus, Insulin-Dependent, 12 17 Carcinoma, Transitional Cell 17 Ovarian Neoplasms 15 Urinary Bladder Neoplasms 14 Triple Negative Breast Neoplasms 14 Mesothelioma 13 Glioblastoma 13 Uterine Cervical Neoplasms 12 Recurrence 12 Multiple Myeloma 11 Lymphoma 11 Clear-cell metastatic renal cell carcinoma 11

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Microarray Analysis 1 Ipilimumab 1 Genetic Testing 1 Gene Expression Profiling 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Biopsy 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Ipilimumab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡